Enhancing HER2-low breast cancer detection with quantitative transcriptomics.

IF 7.6 2区医学 Q1 ONCOLOGY

NPJ Breast Cancer Pub Date : 2025-09-01 DOI:10.1038/s41523-025-00817-9

Maria-Anna Misiakou, Maj-Britt Jensen, Maj-Lis Talman, Bent Ejlertsen, Maria Rossing

引用次数: 0

Abstract

Accurate identification of HER2-low breast cancers remains challenging using standard IHC. We analyzed 3182 breast tumors using transcriptomics, revealing detectable ERBB2 mRNA in 86% of IHC 0 cases. Pathological complete response was most prevalent in anti-HER2-treated patients with highest ERBB2 expression. Our results demonstrate that transcriptomics can sensitively detect HER2 expression and stratify patients beyond IHC classification, supporting its use as a complementary biomarker for guiding anti-HER2 therapy decisions.

Abstract Image

查看原文本刊更多论文

定量转录组学增强低her2乳腺癌检测。

使用标准免疫组化技术准确识别her2低水平乳腺癌仍然具有挑战性。我们使用转录组学分析了3182例乳腺肿瘤，在86%的IHC 0病例中发现了可检测到的ERBB2 mRNA。病理完全缓解在ERBB2表达最高的抗her2治疗患者中最为普遍。我们的研究结果表明，转录组学可以灵敏地检测HER2表达，并在IHC分类之外对患者进行分层，支持其作为指导抗HER2治疗决策的补充生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Breast Cancer Medicine-Pharmacology (medical)

CiteScore

10.10

自引率

1.70%

发文量

122

审稿时长

9 weeks

期刊介绍： npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.